Observation vs Progesterone Treatment for Management of Uterine Arteriovenous Malformation
NCT ID: NCT05491343
Last Updated: 2022-08-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
28 participants
INTERVENTIONAL
2022-08-31
2024-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of the Non-inferiority of Resorbable Gelatin Embolization Compared to Embolization Combined With Endometrial Aspiration for the Management of Hemorrhagic Uterine Vascular Abnormalities Following Premature Termination of Pregnancy
NCT07206342
Subendometrial Injection Versus Intrauterine Infusion of Platelet Rich Plasma for Women With Recurrent Implantation Failure
NCT07306871
Low Molecular Weight Heparin on the Adenomyosis Patients'IVF-ET Outcome
NCT04741295
PRP in Intracytoplasmic Sperm Injection
NCT04354363
Comparison of Laparoscopic Cornuostomy and Wedge Resection for Interstitial Pregnancy
NCT03064594
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Conservative management
No interventions assigned to this group
Progesterone treatment
MedroxyPROGESTERone Injection [Depo-Provera]
The drug-induced endometrial changes would likely to prevent the shedding of endometrium, in turn preventing the exposure of AVM.
Other
Follow up using US
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MedroxyPROGESTERone Injection [Depo-Provera]
The drug-induced endometrial changes would likely to prevent the shedding of endometrium, in turn preventing the exposure of AVM.
Other
Follow up using US
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* hemodynamically stable at clinical presentation
Exclusion Criteria
* contraindication to treatment
* US examination not in the US department
18 Years
50 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
HaEmek Medical Center, Israel
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Etty Spiegel
Dr.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0060-22EMC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.